MGC Pharmaceuticals - PDMR Notification
18/07/2023 11:41
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230718:nRSR3972Ga&default-theme=true
RNS Number : 3972G MGC Pharmaceuticals Limited 18 July 2023
MGC Pharmaceuticals Ltd.
PDMR Notification
18 July 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') announces, further to
the Company's "£0.7 million Fundraising" announcement on 14 July 2023,
details of the participation of Persons Discharging Managerial
Responsibilities ("PDMRs") in the Subscription in accordance with the UK
Market Abuse regulations.
Full details of the shares subscribed by the PDMRs in the Subscription are
contained in the disclosure tables below.
Capitalised terms not otherwise defined in this announcement shall have the
same meaning ascribed to them in the Company's announcement made on 14 July
2023.
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Amir Polak
2 Reason for the notification
(a) Position Chief Pharmaceutical Development Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued following participation in fundraise
(d) Currency Price Volume Total
GBP £0.0012 4,416,667 £5,300
Aggregated information
GBP £0.0012 4,416,667 £5,300
(e) Date of transaction 14 July 2023
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Itay Nissim
2 Reason for the notification
(a) Position Chief Manufacturing and Supply Chain Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued following participation in fundraise
(d) Currency Price Volume Total
GBP £0.0012 3,833,333 £4,600
Aggregated information
GBP £0.0012 3,833,333 £4,600
(e) Date of transaction 14 July 2023
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yair Tal
2 Reason for the notification
(a) Position Chief Information Security Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued following participation in fundraise
(d) Currency Price Volume Total
GBP £0.0012 2,166,667 £2,600
Aggregated information
GBP £0.0012 2,166,667 £2,600
(e) Date of transaction 14 July 2023
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yifat Steuer
2 Reason for the notification
(a) Position Chief Operating Officer and Deputy CEO
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued following participation in fundraise
(d) Currency Price Volume Total
GBP £0.0012 5,833,333 £7,000
Aggregated information
GBP £0.0012 5,833,333 £7,000
(e) Date of transaction 14 July 2023
(f) Place of transaction Outside a trading venue
--Ends--
Authorised for release by the Managing Director, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais / Rowan Harland
CEO & Managing Director Joint Company Secretaries
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk) info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
UK Brokers UK Brokers
Peterhouse Capital Oberon Capital
Charles Goodfellow / Lucy Williams / Duncan Vasey Adam Pollock / Aimee McCusker
+44 207 469 0930 +44 203 179 5300
mgcpharma@tavistock.co.uk (mailto:mgcpharma@tavistock.co.uk) adampollock@oberoninvestments.com (mailto:adampollock@oberoninvestments.com)
aimeemccusker@oberoninvestments.com
(mailto:aimeemccusker@oberoninvestments.com)
UK IR/PR Advisers
IDC Advisory
Graham Herring / Tim Metcalfe / Zach Cohen
mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAEXPFDPDEFA
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group